secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2026-08-05T11:17:00+00:00
Accession:  0001193125-26-333853
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport Therapeutics Q2 net loss $56.6M; initiates RAP-219 Phase 3 in focal seizures
--------------------------------------------------------------------------------

- Net loss $56.6M in Q2 2026 vs $26.7M in Q2 2025; R&D spend $51.4M (up from $22.7M).
- Cash $436.1M at June 30, 2026, down from $476.8M at March 31; runway into H2 2029.
- Phase 3 program for RAP-219 in focal onset seizures initiated (FOCUS 1 and FOCUS 2 enrolling).
- Phase 2 bipolar mania trial topline results expected October 2026; RAP-219 half-life now 22 days.
- IND approved in China for RAP-219 Phase 3 trials; RAP-641 IND-enabling activities continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/0001193125-26-333853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-333853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer